Michael D. Banov, M.D. - Curriculum Vitae
American Board of Psychiatry and Neurology-February 1995
American Board of Adolescent Psychiatry-June 1997
Certification in Addiction Psychiatry by American Board of Psychiatry
Certified Clinical Research Investigator (CCRI). Certification by Association of Clinical Research Professionals (ACRP), 2002-2006
Northwest Behavioral Medicine and Northwest Behavioral Research Center
108 Margaret Avenue
Marietta, GA 30060
Northwest Behavioral Medicine and Northwest Behavioral Research Center
11755 Pointe Place, Suite A-1
Roswell, GA 30076
Medical Director, Northwest Behavioral Medicine
Adolescent, Adult, and Geriatric Psychiatry - March 1994 to present
Marietta and Alpharetta, GA
Medical Director, Northwest Behavioral Research Center
Marietta, GA-March 1996 to present
Medical Director and President, Psychsource LLC-A not-for-profit organization committed to providing mental health resource information to the community
Alpharetta, GA-June 1999 to present
Kennestone Hospital - June 1994 to present
Ridgeview Institute - March 1994 to present
Brawner North Hospital. - March 1994 to June 1996
Northside Hospital- June 1995 to June 1996
Charter-Peachford Hospital- June 1995-June 2002
Chief, Department of Psychiatry-August 1997-June 1999
Kennestone Hospital, Marietta, GA
Director of Medical Education, Ridgeview Institute- March 1994 to October 1998
Clinical Instructor in Psychiatry - July 1993 to December 1993
Harvard Medical School, Boston, MA
Assistant Attending Psychiatrist - July 1993 to December 1993
McLean Hospital, Belmont, MA
Chief Resident, Psychotic Disorders Program, McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School - 1992 to 1993
Consultation-Liaison Service, Massachusetts General Hospital, Boston, MA - 1992
Clinical Fellow in Adult Psychiatry, McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School - 1990 to 1993
Medical Internship in Internal Medicine, The University Hospital, Boston University Medical Center - 1989 to 1990
M.D. Emory University School of Medicine, Atlanta, GA - 1986 to 1989
Medical University of South Carolina, Charleston, SC - 1985 to 1986
A.B. Duke University, Durham, NC - Religion - 1984
Tel Aviv University, Tel Aviv, Israel - 1980
The Dr. Henry P&M Page Durkee Laughlin Fellowship Award - 1993
Harry C. and Maida Solomon Award for most outstanding research, Harvard Medical School Consolidated Department of Psychiatry - 1993
Letter of academic achievement, Medical University of South Carolina - 1986
Magna Cum Laude, Duke University - 1984
Class Honors, Dean's List, Duke University - 1981 to 1982
Psychiatric Consultant/Doctor on Call - 1991 to 1993
Human Resource Institute, Boston, MA
Carney Hospital, Boston, MA
Norwood Hospital, Norwood, MA
Waltham-Weston Hospital, Waltham, MA
Psychopharmacology Consultant to geriatric services and day program for chronically mentally ill patients, Tri-City Mental Health and Retardation Center, Everett, MA - 1992 to 1993
Georgia Composite State Board of Medical Examiners-1994 to present. License No. 037945
Commonwealth of Massachusetts Board of Registration in Medicine-1990 to 1996
Diplomate of National Board of Medical Examiners-1990
Lawyer Assistance Committee, State Bar of Georgia-August 2004-present
Georgia Psychiatric Physicians Association, Economic Affairs Committee-August 2004-present
Credentialing Committee, Kennestone Hospital-August 1997-June 2001
Utilization Review Committe, Kennestone Hospital- June 1995-June 2001
Chairman, Continuing Medical Education, Ridgeview Institue-March 1995-October 1998
Outcomes Research Committee, Ridgeview Institute- March 1995-October 1998
Drug Evaluation Committee, Ridgeview Institute- March 1995-August 1997
Economic Affairs Committee, Georgia Psychiatric Physicians Association-Feburary 1994 to June 1996
Medical Records Committee, Brawner Hospital-May 1994-June 1996
Secretary-Treasurer, McLean Residents' Association - 1990 to 1993
McLean Psychopharmacology Journal Club - 1990 to 1993
President, Super Health 2000 - An organization of over 100 health professionals who educate school and community groups on 15 health topics - 1985 to 1986
Banov MD, Kulick, AR, Oepen G, Pope HG. A New Identity for Misidentification Syndromes. Compr Psychiatry, 1993; 34:114-117.
Banov MD, Tohen M, Friedberg J. High Risk of Eosinophilia in Women Treated with Clozapine. J Clin Psychiatry, 1993; 54:466-69.
Banov MD, Zarate CA, Scialabba D, Tohen M, Wines JD, Kolbrener M, Kim JW, Cole JO. Clozapine Therapy in Refractory Affective Disorders: Polarity Predicts Response in Long-Term Follow-Up. J Clin Psychiatry, 1994; 55:295-300.
Sachs GS, Lafer B, Stoll AL, Banov MD, Thibault AB, Tohen M, Rosenbaum JF. A Double- Blind Trial of Bupropion Versus Desipramine for Bipolar Depression. J Clin Psychiatry, 1994; 55:391-93.
Banov MD. Stay Tuned:Recognizing and Treating Attention Deficit Hyperactivity Disorder in Adults. Insight, 1994; 15:28-31.
Stoll AL, Banov MD, Kolbrener M, Mayer PV, Tohen M, Strakowski A, Castillo J, Suppes P, Cohen BM. Neurological Factors Predict a Favorable Valproate Response in Bipolar Disorder. J Clin Psychopharmacology, 1994; 14(5):311-3
Banov, MD. Brain Medicines: Recent Developments in Psychopharmacology. Insight, 1995; 16:24-7.
Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. Is Clozapine a Mood Stabilizer?. J Clin Psychiatry, 1995; 56:108-112.
Pillay SS, Stoll AL, Weiss MK, Tohen M, Zarate CA, Banov MD, Cole JO. EEG Abnormalities Before Clozapine Therapy Predict a Good Clinical Response to Clozapine. Ann Clin Psychiatry, 1996; 8(1):1-5.
Banov MD. Again &Again:Treatment Strategies for Obsessive-Compulsive Spectrum Disorders. Insight, 1997;18:26-9.
Banov MD. Improved Outcome in Fluvoxamine Treated Patients With SSRI-Induced Sexual Dysfunction. J Clin Psychiatry, 1999; 60(12): 866-868
Green, AI, Tohen, M, Patel, JK, et al. Clozapine in the Treatment of Refractory Psychotic Mania. Am J Psychiatry, 2000; 157(6): 982-986.
Banov MD, Zarate CA, Cohen DM, Frankenburg F, Scialabba D, Kolbrener M, Wines JD, Choras P, Tohen M. Successful Long-Term Use of Clozapine in Refractory Psychotic Disorders with Co-morbid Substance Abuse.
CLINICAL PSYCHOPHARMACOLOGY RESEARCH
Northwest Behavioral Research Center, Marietta, GA 1994-Present
A Multicenter, Randomized, Double Blind, Placebo Controlled Study of XXX in the Treatment of Patients with Bipolar I Disorder with Major Depressive Episode, June 2005-present.
A Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Patients with Generalized Anxiety Disorder August 2005-present.
A Randomized Double-Blind Parallel Group Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of XXX in Subjects with Major Depressive Disorder. September 2004-present.
A Multicenter, Double-Blind, Placebo-Controlled, Fixed- Dose, 8 week Evaluation of the Efficacy and Safety of XXX in the Treatment of Bipolar Disorder Patients Currently Experiencing a Major Depressive Episode. September 2004-October 2005.
A Multicenter, Double-Blind, Placebo-Controlled, Fixed- Dose, 8 week Evaluation of the Efficacy and Sfaety of XXX in the Treatment of Major Depression in Patients with Type II Bipolar Disorder. February 2003-October 2005.
A Multicenter, Randomized, Parallel-group, Double-Blind, Phase III Comparison of the Efficacy and Safety of XXX When Used as Adjunct to Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder in Adult Patients. March 2004-present.
A Phase III, Randomized, Double Blind, Multicneter, Placebo Contorlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of XXX in Adults with Attention Deficit Hyperactivity Disorder June 2005-September 2005
XXX verses Divalproex and Placebo in the Treatment of Mild to Moderate Mania Asscoiated with Bipolar Disorder October 2004- present
XXX verses Lamotrigine in the Treatment of Bipolar I Disorder October 2003-October 2005
An 8-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Fixed Dose Study Comparing the Efficacy and Safety of XXX or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. September 2002 to June 2003.
A Study of XXX plus XXX in Combination for Treatment-Resistant Depression without Psychotic Features. February 2002 to September 2005.
An Eight-week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of 2 Doses of XXX and Paroxetine in Subjects with Major Depressive Disorder. October 2001 to November 2002.
A 24-Month, Open-Label Study of XXX in Adults with Attention Deficit Hyperactivity Disorder. January 2002 to July 2004.
A Randomized, Double Blind, Placebo-controlled, Parallel-Group Study of XXX in Adults with Attention Deficit Hyperactivity Disorder. January 2002 to September 2002.
A randomized, double-blind, parallel-group, placebo-controlled, study evaluating efficacy and safety of XXX versus placebo in patients with Major Depressive Disorder. September 2001 to July 2002.
A double-blind, randomized, placebo-controlled, 3-month clinical trial of XXX and XXXin the treatment of Posttrauamatic Stress Disorder. August 1999 to February 2000.
A randomized, double-blind, placebo-controlled, flexible dosage trial to evaluate the efficacy and tolerability of XXX in patients with Generalized Anxiety Disorder. June 1999-January 2000.
A double-blind, placebo controlled, fixed-dosage study comparing the efficacy and tolerability of XXX and XXX to placebo in the treatment of Major Depressive Disorder with anxiety. March 2001 to September 2001.
A Six-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of XXX and XXX in Subjects with Major Depression. June 2000 to January 2001.
Open-Label Combination of XXX and XXX in Major Depressive Disorder. February 2000 to June 2002.
A Phase III, Open-Label, Treatment-Switching Study from Orally Administered Antipsychotic Monotherapy to Orally Administered XXX Monotherapy in the Treatment of Chronic Schizophrenia and Schizoaffective Patients. November 1999-July 2000.
XXX Versus Placebo in the Prevention of Relapse in Bipolar Disorder. July 1999-March 2002.
A 12-Week, Randomized, Double-blind, Placebo Controlled, Flexible Dose Study of XXX in the Treatment of Generalized Social Anxiety Disorder. August 1999-February 2000.
A Multicenter, Open-Label, Long-Term, Safety and Efficacy Study of XXX Tablets Once Daily in Subjects With Schizophrenia or Other Psychotic Disorders. September 1998-September 1999.
A 12 week, Double-blind, Placebo controlled, parallel group study to assess the efficacy and tolerability of XXX in Patients suffering from Posttraumatic Stress Disorder (PSTD). January 1999-February 2000.
Olanzapine Verses Placebo in the Treatment of Bipolar Disorder, Manic or Mixed. Eli Lilly. January 1998-November 1998.
Quetiapine (Seroquel) Experience with Safety and Tolerability (Quest). Zeneca Limited. August 1997-March 1998.
Seroquel in Treatment of Schizophrenia, Schizoaffective, and Bipolar Disorder. Zeneca Limited. February 1997-July 1997.
Venlafaxine vs. Fluoxetine vs. Placebo in Inpatient Treatment of Melancholic Depression.
Wyest-Ayerst Laboratories. February 1997-July 1997.
Double-Blind Dose Comparison of IM Ziprasidone Mesylate in Psychosis with Acute Agitation. Pfizer Pharmaceuticals. January 1997- July 1997.
Additional Research Experience:
McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School, Belmont, MA. 1992-1994
Clozapine in Acute Mania - Prospective study to evaluate the safety and efficacy of clozapine in the treatment of refractory acute bipolar mania and psychotic features.
First Psychosis Project - Prospective study to determine characteristics, outcome and response to treatment of all first hospitalized psychotic patients.
Meta-analysis of Clozapine in the Treatment of Acute Psychosis - Literature review analysis of double-blind studies comparing clozapine to typical neuroleptics.
Psychiatry for the Non-Psychiatrist. Georgia Academy of Family Physicians. 52nd Annual Scientific Assembly and Exhibition. November 3, 2000
New Developments in Wakefulness Medications. Continuing Medical Education Series. Summit Ridge Hospital. Lawrenceville, Georgia. October 19, 2000
New Medications for Mental Illness. NAMI-GA Convention. October 14, 2000
Managing Social Axiety Disorder. Atlanta Steeplechase. SmithKline Beecham. April 15, 2000.
Zyprexa Approved For Treatment of Acute Mania. WSB-TV Interview. Atlanta GA, April 5, 2000
Anticonvulsants in the Management of Bipolar Disorder. Abbott Laboratories. Phillips Arena. Atlanta GA, November 15 1999.
Anxiety Disorders. WSTR-FM. “Steve and Vickie in the Morning”. Atlanta, GA, October 6, 1999
Social Anxiety Disorder. WXIA-TV (NBC). Atlanta GA, October 5, 1999
New Options For Managing Social Anxiety Disorder. WSB-AM (CNN Radio). Atlanta GA, October 5, 1999
New Directions in the Treatment of Bipolar Disorder. Continuing Medical Education Series. Ridgeview Institute. March 3, 1999
Community Discussion About Obsessive-Compulsive Disorder with Marc Summers. Westin Atlanta North at Perimeter. February 25, 1999.
Treatment Issues in Violent Mentally Ill Patients.Clayton County Mental Health Center. Morganton NC, April 20, 1998.
New Advances in Psychopharmacology. Student Assistance Professionals Association, Atlanta, GA, February 18,1998.
Hypochondriasis. WGNX-TV 46 News. September 1997.
The Dangers of Huffing. WGNX-TV 46 News. August 1997.
Assessment and Treatment Strategies in Working with the Patient with Attention Deficit Hyperactivity Disorder. Medical Association of Georgia, Scientific Assembly, Atlanta, GA. November 17, 1995.
Recent Developments in Psychopharmacology. Ridgeview Institute CME Tape Learning Series. October, 1995.
Medicines in Psychiatry. WSB Radio 750. August 1995.
Diagnosing and Treating ADHD in Adults. Ridgeview Institute, Seminars for Clinicians, Atlanta, GA. April 28, 1995.
Seasonal Affective Disorder. Ridgeview Institute, Family Learning Series, Atlanta, GA. January 26, 1995.
Is Clozapine Monotherapy an Effective Mood Stabilizer? Presented at American College of Neuropsychopharmacology, Honolulu, Hawaii, December 17, 1993.
Clozapine Therapy in Refractory Affective Disorders: Polarity Predicts Response in Long-Term Follow-Up. Presented at the American Psychiatric Association Annual Meeting, San Francisco, CA, May 24, 1993.
Clozapine in Affective Disorders. Psychopharmacology Series, Affective Disorders Program, McLean Hospital, May 6, 1993.
Successful Use of Clozapine in Refractory Psychosis with Co-morbid Substance Abuse: A Long Term Follow-Up Study. Harvard Medical School Consolidated Department of Psychiatry Research Day, April 21, 1993.
Clozapine as Maintenance Therapy in Affective Illnesses. Presented at The Boston Society of Neurology and Psychiatry, Cobb Assembly, March 25, 1993.
Obsessive/Compulsive Symptoms in Psychotic Patients: Related or Distinct Entities? The Banov MD, Moderator, Clinical Case Conference. McLean Hospital Department of Postgraduate and Continuing Medical Education, January 19, 1993.
Sachs GS, Stoll AL, Lafer B, Banov M, Thibeault A, Tohen M, Falk W, Zornberg G, Rosenbaum J, Cohen BM. Bupropion versus Desipramine in Bipolar Depression. Double-blind comparison of acute and maintenance effects. Presented at the Second International Conference on Refractory Depression, Amsterdam, The Netherlands, June 24-26, 1992.
American Psychiatric Association - 1990 to present
Georgia Psychiatric Association 1994 to present
Massachusetts Psychiatric Association - 1990 to 1994
American Medical Association - 1989 to present
Available on request.